Although non-small cell lung cancer (NSCLC), ovarian, colon, and pancreatic cancers overexpress HER2 protein and/or show gene amplification in varying proportions of cases, HER2 protein overexpression is most pronounced in breast and gastric cancers (21). This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.